Skip to content

Effect of dexmedetomidine on chemotherapy-induced peripheral neuropathy in breast cancer patients

Effect of dexmedetomidine on chemotherapy-induced peripheral neuropathy in breast cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100553
Enrollment
Unknown
Registered
2025-04-10
Start date
2023-04-01
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chemotherapy-induced peripheral neuropathy

Interventions

Group A:Dexmedetomidine was continuously infused at 0.5 µg/kg 10 min before operation and then 0.4 µg/(kg·h) until 30 min before operation. PCIA was connected at the end of surgery. In group A, butorp
Group B:After continuous infusion of dexmedetomidine 0.5 µg / kg at 10 min before operation, it was maintained at 0.4 µg / ( kg · h ) until 30 min before operation. At the end of the operation, the in
Group N:Saline was pumped at the same speed. PCIA was connected at the end of the operation. In group B, the formula was 0.15 mg/kg butorphanol + ondansetron 16 mg.

Sponsors

Yunnan Provincial Tumor Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. patients who underwent modified radical mastectomy under elective general anesthesia; 2. patients who clearly had CIPN after preoperative neoadjuvant chemotherapy and whose symptoms did not subside were selected; 3. ASA grade I ~ III ; 4. Age> 18 years old.

Exclusion criteria

Exclusion criteria: 1. patients with diabetes; 2. patients with definite history of nervous system and mental system diseases before chemotherapy; 3. having a history of drug abuse or long-term opioid use; 4. patients with sinus bradycardia or heart block and ventricular dysfunction before surgery; 5. patients with severe liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Subjective symptom outcome;Total Neuropathy Score clinical version;The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-item scale;

Secondary

MeasureTime frame
2ml peripheral venous blood was collected to measure the inflammatory cytokines IL-6, TNF-a, IL-2, IL-10, IFN-?;

Countries

China

Contacts

Public ContactLei Lequn/ Wang Zhonghui

Department of Anesthesiology, Yunnan Provincial Tumor Hospital, No.519, Kunzhou Road, Kunming City, Yunnan Province, China

leilequn@126.com+86 188 8703 8361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026